A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

British Journal of Haematology

Volumn 163, Issue 3, 2013, Pages 334-342

  Coiffier, Bertrand ^a   Radford, John ^b   Bosly, André ^c   Martinelli, Giovanni ^d   Barca, Gabriela ^e   Davies, Andrew ^f   Decaudin, Didier ^g   Gallop Evans, Eve ^h   Padmanabhan Iyer, Swaminathan ⁱ   Van Eygen, Koen ^j   Wu, Ka Lung ^k   Gupta, Ira V ^l   Lin, Thomas S ^l   Goldstein, Nancy ^l   Jewell, Roxanne C ^l   Winter, Paul ^m   Lisby, Steen ⁿ  

^a HOSPICES CIVILS DE LYON   (France)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e Spitalul Clinic Coltea Bucuresti   (Romania)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g INSTITUT CURIE   (France)

^h VELINDRE CANCER CENTRE   (United Kingdom)

ⁱ CTRC Institute for Drug Development   (United States)

^j Oncologisch Centrum   (Belgium)

^k Ziekenhuis Stuivenberg   (Belgium)

^l GLAXOSMITHKLINE   (United States)

^m GLAXOSMITHKLINE   (United Kingdom)

ⁿ Genmab   (Denmark)

more..

Author keywords

Diffuse large B cell lymphoma; Haematological malignancies; Immunotherapy; Lymphoid malignancies; Non Hodgkin lymphoma

Indexed keywords

CD20 ANTIBODY; CETIRIZINE; OFATUMUMAB; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CATHETER INFECTION; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HERPES SIMPLEX; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

DIFFUSE LARGE B-CELL LYMPHOMA; HAEMATOLOGICAL MALIGNANCIES; IMMUNOTHERAPY; LYMPHOID MALIGNANCIES; NON-HODGKIN LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; YOUNG ADULT;

EID: 84885428115     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12537     Document Type: Article

References (18)

1. Armitage, J.O. (2007) How I treat patients with diffuse large B-cell lymphoma. Blood, 110, 29-36.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V. & International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
3. Cillessen, S.A.G.M., Mackus, W.J.M., Castricum, K.C.M., Vos, W., Kortman, P.C., van de Winkel, J.G.J., Parren, W.H.I., Meijer, C.J.L.M. & Oudejans, J.J. (2007) Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) are effectively killed by Ofatumumab-induced complement-mediated cytoxicity. Blood (ASH Annual Meeting Abstracts), 110, 2346.
4. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. & Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 1927-1932.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
6. Czuczman, M.S., Fayad, L., Delwail, V., Cartron, G., Jacobsen, E., Kuliczkowski, K., Link, B.K., Pinter-Brown, L., Radford, J., Hellmann, A., Gallop-Evans, E., DiRienzo, C.G., Goldstein, N., Gupta, I., Jewell, R.C., Lin, T.S., Lisby, S., Schultz, M., Russell, C.A., Hagenbeek, A. & Study, I. (2012a) Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood, 119, 3698-3704.
7. Czuczman, M.S., Hess, G., Gadeberg, O.V., Pedersen, L.M., Goldstein, N., Gupta, I., Jewell, R.C., Lin, T.S., Lisby, S., Strange, C., Windfeld, K., Viardot, A. & Study, I. (2012b) Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. British Journal of Haematology, 157, 438-445.
8. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
9. Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., Link, B.K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N. & Radford, J. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111, 5486-5495.
10. Matasar, M.J., Czuczman, M.S., Rodriguez, M.A., Fennessy, M., Shea, T.C., Spitzer, G., Lossos, I.S., Kharfan-Dabaja, M.A., Joyce, R., Fayad, L., Liao, Q., Edvardsen, K., Lisby, S. & Moskowitz, C.H. (2011) A Phase II Study of Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B-cell lymphoma prior to Autologous Stem Cell Transplantation (ASCT). Blood (ASH Annual Meeting Abstracts), 118, 957.
11. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265-276.
12. Muller, C., Murawski, N., Wiesen, M.H., Held, G., Poeschel, V., Zeynalova, S., Wenger, M., Nickenig, C., Peter, N., Lengfelder, E., Metzner, B., Rixecker, T., Zwick, C., Pfreundschuh, M. & Reiser, M. (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood, 119, 3276-3284.
13. Smith, A., Howell, D., Patmore, R., Jack, A. & Roman, E. (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. British Journal of Cancer, 105, 1684-1692.
14. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. & van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. The Journal of Immunology, 177, 362-371.
15. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's lymphoma classification project. Blood, 89, 3909-3918.
16. + NHL: a prospective randomized HOVON trial. Blood, 111, 537-543.
17. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A., Osterborg, A. & Hx, C.D.S.I. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
18. Wierda, W.G., Padmanabhan, S., Chan, G.W., Gupta, I.V., Lisby, S., Osterborg, A. & Hx, C.D.S.I. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood, 118, 5126-5129.